|
US6346611B1
(en)
*
|
1990-06-11 |
2002-02-12 |
Gilead Sciences, Inc. |
High affinity TGfβ nucleic acid ligands and inhibitors
|
|
US6395888B1
(en)
*
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US6344321B1
(en)
*
|
1990-06-11 |
2002-02-05 |
Gilead Sciences, Inc. |
Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
|
|
US6229002B1
(en)
|
1995-06-07 |
2001-05-08 |
Nexstar Pharmaceuticlas, Inc. |
Platelet derived growth factor (PDGF) nucleic acid ligand complexes
|
|
US6242246B1
(en)
|
1997-12-15 |
2001-06-05 |
Somalogic, Inc. |
Nucleic acid ligand diagnostic Biochip
|
|
AU2004242462B2
(en)
*
|
1999-07-29 |
2008-01-24 |
Gilead Sciences, Inc. |
Nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor C-Met and to integrins
|
|
PT1401853E
(pt)
|
2001-05-25 |
2010-12-07 |
Univ Duke |
Modulador de oligonucleotídeos
|
|
US7879991B2
(en)
*
|
2002-05-06 |
2011-02-01 |
Noxxon Pharma Ag |
CGRP binding nucleic acids
|
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
|
CA2487809A1
(en)
*
|
2002-06-18 |
2003-12-24 |
Archemix Corp. |
Aptamer-toxin molecules and methods for using same
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US10100316B2
(en)
*
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
US20050124565A1
(en)
*
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US8039443B2
(en)
*
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20040253243A1
(en)
*
|
2003-01-21 |
2004-12-16 |
David Epstein |
Aptamer therapeutics useful in ocular pharmacotherapy
|
|
EP2623601B1
(en)
|
2003-04-21 |
2015-02-18 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20040219663A1
(en)
*
|
2003-04-30 |
2004-11-04 |
Page Robert D. |
Biopolymer array fabrication using different drop deposition heads
|
|
US7727969B2
(en)
*
|
2003-06-06 |
2010-06-01 |
Massachusetts Institute Of Technology |
Controlled release nanoparticle having bound oligonucleotide for targeted delivery
|
|
PL1660057T3
(pl)
|
2003-08-27 |
2012-10-31 |
Ophthotech Corp |
Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
|
|
PL3385384T3
(pl)
|
2004-02-12 |
2021-03-08 |
Archemix Llc |
Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
US20060193821A1
(en)
*
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
|
RU2006135119A
(ru)
*
|
2004-03-05 |
2008-04-10 |
Аркемикс Корп. (Us) |
Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний
|
|
US20080214489A1
(en)
*
|
2004-04-19 |
2008-09-04 |
Anthony Dominic Keefe |
Aptamer-mediated intracellular delivery of oligonucleotides
|
|
US7579450B2
(en)
*
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
|
MX2007002772A
(es)
|
2004-09-07 |
2008-03-05 |
Archemix Corp |
Aptameros para el factor de von willebrand y su uso como agentes terapeuticos para la enfermedad trombotica.
|
|
EP1791557A4
(en)
*
|
2004-09-07 |
2009-09-23 |
Archemix Corp |
MEDICAL CHEMISTRY USING APTAMERS
|
|
US7566701B2
(en)
*
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
EP3034089A1
(en)
|
2004-11-02 |
2016-06-22 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
WO2006100449A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
AU2006265896B2
(en)
|
2005-06-30 |
2012-05-31 |
Archemix Corp. |
Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
|
|
CA2626325A1
(en)
|
2005-10-28 |
2007-05-10 |
Praecis Pharmaceuticals Incorporated |
Methods for identifying compounds of interest using encoded libraries
|
|
US7922000B2
(en)
*
|
2006-02-15 |
2011-04-12 |
Miraial Co., Ltd. |
Thin plate container with a stack of removable loading trays
|
|
HUE026496T2
(en)
*
|
2006-03-08 |
2016-06-28 |
Archemix Llc |
Complement-binding aptamers and anti-C5 agents for treating eye diseases
|
|
WO2008134077A1
(en)
*
|
2007-04-30 |
2008-11-06 |
Archemix Corp. |
Metabolic profile directed aptamer medicinal chemistry
|
|
US20090203766A1
(en)
*
|
2007-06-01 |
2009-08-13 |
Archemix Corp. |
vWF aptamer formulations and methods for use
|
|
US20080305157A1
(en)
*
|
2007-06-08 |
2008-12-11 |
University Of Maryland Office Of Technology Commercialization |
Encapsulation and separation of charged organic solutes inside catanionic vesicles
|
|
US20090233295A1
(en)
*
|
2008-01-29 |
2009-09-17 |
Elias Georges |
Trim59 directed diagnostics for neoplastic disease
|
|
US8207298B2
(en)
*
|
2008-05-01 |
2012-06-26 |
Archemix Corp. |
Methods of separating biopolymer conjugated molecules from unconjugated molecules
|
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
|
JP2012519281A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
GB0904957D0
(en)
|
2009-03-23 |
2009-05-06 |
Univ Erasmus Medical Ct |
Tumour gene profile
|
|
GB0915515D0
(en)
|
2009-09-04 |
2009-10-07 |
Ucl Business Plc |
Treatment of vasculoproliferative conditions
|
|
US8236570B2
(en)
*
|
2009-11-03 |
2012-08-07 |
Infoscitex |
Methods for identifying nucleic acid ligands
|
|
US8841429B2
(en)
*
|
2009-11-03 |
2014-09-23 |
Vivonics, Inc. |
Nucleic acid ligands against infectious prions
|
|
CA2832672A1
(en)
|
2010-04-16 |
2011-10-20 |
Nuevolution A/S |
Bi-functional complexes and methods for making and using such complexes
|
|
GB201013573D0
(en)
|
2010-08-12 |
2010-09-29 |
Ucl Business Plc |
Treatment
|
|
GB201013785D0
(en)
|
2010-08-17 |
2010-09-29 |
Ucl Business Plc |
Treatment
|
|
GB201014026D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucl Business Plc |
Treatment
|
|
WO2012038744A2
(en)
|
2010-09-22 |
2012-03-29 |
Genome Research Limited |
Detecting mutations
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
GB201120711D0
(en)
|
2011-12-01 |
2012-01-11 |
Univ Erasmus Medical Ct |
Method for classifying tumour cells
|
|
SG11201403769YA
(en)
|
2012-01-10 |
2014-07-30 |
Noxxon Pharma Ag |
Nucleic acids specifically binding cgrp
|
|
WO2013132267A1
(en)
|
2012-03-09 |
2013-09-12 |
Ucl Business Plc |
Treatment of cancer
|
|
WO2013149086A1
(en)
|
2012-03-28 |
2013-10-03 |
Somalogic, Inc. |
Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
|
|
GB201205739D0
(en)
|
2012-03-30 |
2012-05-16 |
Ucl Business Plc |
Treatment of acute inflammation in the respiratory tract
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
MX2016000364A
(es)
|
2013-07-12 |
2016-05-09 |
Ophthotech Corp |
Metodos para tratar o prevenir afecciones oftalmologicas.
|
|
CA3221709A1
(en)
|
2013-09-09 |
2015-03-12 |
Somalogic Operating Co., Inc. |
Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
BR112016021547A2
(pt)
|
2014-03-17 |
2017-10-03 |
Glaxosmithkline Ip Dev Ltd |
Aptâmeros para envio tópico
|
|
US9605266B2
(en)
|
2014-07-16 |
2017-03-28 |
City Of Hope |
Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore
|
|
JP6661645B2
(ja)
|
2014-10-15 |
2020-03-11 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
トランスフェリン受容体（ｔｆｒ）に対するｒｎａアプタマー
|
|
BR112018010005A2
(pt)
|
2015-11-18 |
2018-11-21 |
Formycon Ag |
seringa pré-carregada, e, kit
|
|
EP4556023A3
(en)
|
2015-11-18 |
2025-10-15 |
Formycon AG |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
|
US11654046B2
(en)
|
2015-11-18 |
2023-05-23 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
|
US10576128B2
(en)
|
2016-01-26 |
2020-03-03 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
GB201704953D0
(en)
|
2017-03-28 |
2017-05-10 |
Imp Innovations Ltd |
Natural killer cells
|
|
EP3630062A2
(en)
|
2017-05-24 |
2020-04-08 |
SiO2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
US20200237997A1
(en)
|
2017-05-24 |
2020-07-30 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
US11807623B2
(en)
|
2017-11-30 |
2023-11-07 |
Arrakis Therapeutics, Inc. |
Nucleic acid-binding photoprobes and uses thereof
|
|
GB201804515D0
(en)
|
2018-03-21 |
2018-05-02 |
Takayuki Takakondo |
Treatment of necroptosis
|
|
GB201804514D0
(en)
|
2018-03-21 |
2018-05-02 |
Ucl Business Plc |
Treatment of pyroptosis
|
|
GB201804922D0
(en)
|
2018-03-27 |
2018-05-09 |
Ucl Business Plc |
Traatment
|
|
GB202002711D0
(en)
|
2020-02-26 |
2020-04-08 |
Ucl Business Ltd |
Treatment
|
|
IL299215A
(en)
|
2020-06-25 |
2023-02-01 |
Medimmune Ltd |
Prevention of axonal damage through binding of an antibody to amyloid beta 1-42
|
|
JP2023541632A
(ja)
|
2020-09-15 |
2023-10-03 |
インペリアル・カレッジ・イノベーションズ・リミテッド |
特発性肺線維症の処置
|
|
GB202017673D0
(en)
|
2020-11-09 |
2020-12-23 |
Imperial College Innovations Ltd |
Treatment of pulmonary arterial hypertensive
|
|
US20250127784A1
(en)
|
2022-02-09 |
2025-04-24 |
Imperial College Innovations Limited |
Treatment of Telangiectasia
|
|
WO2024047368A1
(en)
|
2022-09-02 |
2024-03-07 |
Imperial College Innovations Limited |
Natural killer cells
|
|
GB202303784D0
(en)
|
2023-03-15 |
2023-04-26 |
Institute Of Cancer Res Royal Cancer Hospital |
Cancer treatment
|
|
WO2024261477A1
(en)
|
2023-06-20 |
2024-12-26 |
Yaqrit Limited |
Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate
|